Applied BioCode (6598.TW) Akcija Цена

Applied BioCode Цена

TWSE·ZATVORENO
30,20TWD+1,45 (+4,92 %)
Tržište je zatvoreno

Revenue has compounded at 27,1% per year over the past 12 years to 475,20 М TWD. Applied BioCode's net margin stands at -42,3%, up from -51,6% several years earlier. The stock trades about 57% above its 52-week low.

Cena akcije Applied BioCode

Obim trgovanja
Детаљи

Цена акције

Како читати овај графикон

Овај графикон прати историјску цену акције компаније Applied BioCode кроз време. Можете пребацивати између дневног, недељног и месечног приказа и одабрати прилагођене временске опсеге — од једног дана до целокупне доступне историје. Користите пребацивач да видите промене цене у апсолутним валутним износима или као процентуалну промену у односу на почетни датум.

Укупан повраћај наспрам повраћаја цене

Пребацивач "Укупан повраћај" укључује реинвестиране дивиденде поред чистог кретања цене. Ово је критично јер дивиденде могу представљати значајан део дугорочних повраћаја. Историјски, отприлике 40% укупног повраћаја S&P 500 је дошло од дивиденди. Увек упоредите укупан повраћај при процени реалне перформансе акције наспрам референтне вредности.

Интрадневни подаци о ценама

При прегледу временског оквира од једног дана, графикон приказује кретање цене у реалном времену интрадневно. Ово је корисно за посматрање како акција компаније Applied BioCode реагује на отварање тржишта, пријаву добити или разбијајуће вести током трговачке сесије.

Шта потражити

Потражите дугорочне трендове (одржана кретања нагоре или наниже кроз месеце и године), нивое подршке и отпора (зоне цена где се акција редовно одбива или враћа), и волатилност (колико цена флуктуира дан по дан). Поређење графикона цена акције Applied BioCode са индексом тржишта као S&P 500 може открити да ли акција надмашује или сузостаје ширег тржишта.

Applied BioCode Istorija cene akcije
DatumApplied BioCode Cena
31. 7. 2026.30,20 TWD
30. 7. 2026.28,75 TWD
29. 7. 2026.29,85 TWD
28. 7. 2026.29,10 TWD
27. 7. 2026.30,00 TWD
24. 7. 2026.27,70 TWD
23. 7. 2026.28,80 TWD
22. 7. 2026.27,85 TWD
21. 7. 2026.26,65 TWD
20. 7. 2026.26,85 TWD
17. 7. 2026.27,65 TWD
16. 7. 2026.25,20 TWD
15. 7. 2026.26,15 TWD
14. 7. 2026.23,80 TWD
13. 7. 2026.24,80 TWD
10. 7. 2026.22,85 TWD
9. 7. 2026.22,85 TWD
8. 7. 2026.22,75 TWD
7. 7. 2026.22,95 TWD
6. 7. 2026.23,25 TWD
3. 7. 2026.23,05 TWD
2. 7. 2026.22,75 TWD
1. 7. 2026.22,50 TWD
30. 6. 2026.22,85 TWD
29. 6. 2026.22,85 TWD
26. 6. 2026.22,80 TWD
25. 6. 2026.22,90 TWD
24. 6. 2026.23,20 TWD
23. 6. 2026.23,45 TWD
22. 6. 2026.23,75 TWD
18. 6. 2026.24,15 TWD
17. 6. 2026.24,40 TWD
16. 6. 2026.24,40 TWD
15. 6. 2026.25,00 TWD
12. 6. 2026.24,60 TWD
11. 6. 2026.24,50 TWD
10. 6. 2026.24,90 TWD
9. 6. 2026.25,00 TWD
8. 6. 2026.24,50 TWD
5. 6. 2026.24,50 TWD
4. 6. 2026.24,50 TWD
3. 6. 2026.24,10 TWD
2. 6. 2026.24,30 TWD
1. 6. 2026.24,20 TWD
29. 5. 2026.24,75 TWD
28. 5. 2026.24,75 TWD
27. 5. 2026.24,95 TWD
26. 5. 2026.24,85 TWD
25. 5. 2026.24,50 TWD
22. 5. 2026.24,30 TWD
21. 5. 2026.24,30 TWD
20. 5. 2026.24,20 TWD
19. 5. 2026.24,65 TWD
18. 5. 2026.24,50 TWD
15. 5. 2026.24,35 TWD
14. 5. 2026.23,75 TWD
13. 5. 2026.24,15 TWD
12. 5. 2026.23,35 TWD
11. 5. 2026.22,70 TWD
8. 5. 2026.22,50 TWD
7. 5. 2026.22,60 TWD
6. 5. 2026.22,90 TWD
5. 5. 2026.22,55 TWD
4. 5. 2026.22,55 TWD
30. 4. 2026.21,45 TWD
29. 4. 2026.21,95 TWD
28. 4. 2026.21,90 TWD
27. 4. 2026.21,90 TWD
24. 4. 2026.21,95 TWD
23. 4. 2026.21,85 TWD
22. 4. 2026.22,15 TWD
21. 4. 2026.22,25 TWD
20. 4. 2026.22,70 TWD
17. 4. 2026.22,80 TWD
16. 4. 2026.22,90 TWD
15. 4. 2026.22,80 TWD
14. 4. 2026.22,60 TWD
13. 4. 2026.22,60 TWD
10. 4. 2026.22,00 TWD
9. 4. 2026.21,80 TWD
8. 4. 2026.22,80 TWD
7. 4. 2026.22,55 TWD
2. 4. 2026.23,10 TWD
1. 4. 2026.23,40 TWD
31. 3. 2026.22,65 TWD
30. 3. 2026.23,30 TWD
27. 3. 2026.23,35 TWD
26. 3. 2026.23,55 TWD
25. 3. 2026.24,15 TWD
24. 3. 2026.23,65 TWD
23. 3. 2026.24,25 TWD
20. 3. 2026.24,95 TWD
19. 3. 2026.25,00 TWD
18. 3. 2026.24,80 TWD
17. 3. 2026.24,60 TWD
16. 3. 2026.24,80 TWD
13. 3. 2026.25,05 TWD
12. 3. 2026.24,55 TWD
11. 3. 2026.25,30 TWD
10. 3. 2026.23,90 TWD
9. 3. 2026.23,60 TWD
6. 3. 2026.24,65 TWD
5. 3. 2026.24,50 TWD
26. 2. 2026.25,30 TWD
25. 2. 2026.24,55 TWD
24. 2. 2026.24,35 TWD
23. 2. 2026.24,50 TWD
11. 2. 2026.24,05 TWD
10. 2. 2026.24,05 TWD
9. 2. 2026.25,65 TWD
6. 2. 2026.23,35 TWD
5. 2. 2026.24,30 TWD
4. 2. 2026.24,40 TWD
3. 2. 2026.24,10 TWD
2. 2. 2026.23,60 TWD
30. 1. 2026.24,10 TWD
29. 1. 2026.24,05 TWD
28. 1. 2026.24,80 TWD
27. 1. 2026.24,15 TWD
26. 1. 2026.23,95 TWD
23. 1. 2026.23,60 TWD
22. 1. 2026.24,05 TWD
21. 1. 2026.23,45 TWD
20. 1. 2026.23,90 TWD
19. 1. 2026.24,50 TWD
16. 1. 2026.24,45 TWD
15. 1. 2026.24,60 TWD
13. 1. 2026.23,40 TWD
12. 1. 2026.24,25 TWD
9. 1. 2026.23,15 TWD
8. 1. 2026.23,05 TWD
7. 1. 2026.22,30 TWD
6. 1. 2026.22,40 TWD
5. 1. 2026.22,35 TWD
2. 1. 2026.22,00 TWD
31. 12. 2025.22,00 TWD
30. 12. 2025.22,00 TWD
29. 12. 2025.22,30 TWD
26. 12. 2025.22,05 TWD
24. 12. 2025.21,60 TWD
23. 12. 2025.22,00 TWD
22. 12. 2025.22,10 TWD
19. 12. 2025.21,50 TWD
18. 12. 2025.21,25 TWD
17. 12. 2025.21,10 TWD
16. 12. 2025.21,10 TWD
15. 12. 2025.21,25 TWD
12. 12. 2025.21,10 TWD
11. 12. 2025.21,40 TWD
10. 12. 2025.21,45 TWD
9. 12. 2025.21,30 TWD
8. 12. 2025.21,40 TWD
5. 12. 2025.21,55 TWD
4. 12. 2025.21,40 TWD
3. 12. 2025.21,65 TWD
2. 12. 2025.21,65 TWD
1. 12. 2025.21,75 TWD
28. 11. 2025.22,10 TWD
27. 11. 2025.21,70 TWD
26. 11. 2025.21,55 TWD
25. 11. 2025.21,35 TWD
24. 11. 2025.21,20 TWD
21. 11. 2025.21,20 TWD
20. 11. 2025.20,95 TWD
19. 11. 2025.20,55 TWD
18. 11. 2025.21,00 TWD
17. 11. 2025.21,00 TWD
14. 11. 2025.21,10 TWD
13. 11. 2025.21,25 TWD
12. 11. 2025.21,30 TWD
11. 11. 2025.21,85 TWD
10. 11. 2025.22,70 TWD
7. 11. 2025.23,10 TWD
6. 11. 2025.22,70 TWD
5. 11. 2025.22,70 TWD
4. 11. 2025.22,65 TWD
3. 11. 2025.22,80 TWD
31. 10. 2025.22,90 TWD
30. 10. 2025.23,00 TWD
29. 10. 2025.22,55 TWD
28. 10. 2025.23,05 TWD
27. 10. 2025.23,00 TWD
23. 10. 2025.23,10 TWD
22. 10. 2025.23,15 TWD
21. 10. 2025.23,00 TWD
20. 10. 2025.23,10 TWD
17. 10. 2025.23,00 TWD
16. 10. 2025.22,95 TWD
15. 10. 2025.22,85 TWD
14. 10. 2025.22,75 TWD
13. 10. 2025.23,00 TWD
9. 10. 2025.23,10 TWD
8. 10. 2025.22,70 TWD
7. 10. 2025.22,95 TWD
3. 10. 2025.22,55 TWD
2. 10. 2025.22,60 TWD
1. 10. 2025.23,30 TWD
30. 9. 2025.23,65 TWD
26. 9. 2025.23,60 TWD
25. 9. 2025.23,00 TWD
24. 9. 2025.22,65 TWD
23. 9. 2025.22,60 TWD
22. 9. 2025.22,45 TWD
19. 9. 2025.22,70 TWD
18. 9. 2025.22,95 TWD
17. 9. 2025.23,05 TWD
16. 9. 2025.23,10 TWD
15. 9. 2025.23,05 TWD
12. 9. 2025.23,15 TWD
11. 9. 2025.23,35 TWD
10. 9. 2025.23,35 TWD
9. 9. 2025.23,25 TWD
8. 9. 2025.21,40 TWD
5. 9. 2025.20,85 TWD
4. 9. 2025.22,00 TWD
3. 9. 2025.20,60 TWD
2. 9. 2025.19,70 TWD
1. 9. 2025.19,35 TWD
29. 8. 2025.19,60 TWD
28. 8. 2025.19,55 TWD
27. 8. 2025.19,55 TWD
26. 8. 2025.19,55 TWD
25. 8. 2025.19,60 TWD
22. 8. 2025.19,35 TWD
21. 8. 2025.19,35 TWD
20. 8. 2025.19,25 TWD
19. 8. 2025.19,30 TWD
18. 8. 2025.19,55 TWD
15. 8. 2025.19,55 TWD
14. 8. 2025.19,55 TWD
13. 8. 2025.19,50 TWD
12. 8. 2025.19,50 TWD
11. 8. 2025.19,50 TWD
8. 8. 2025.19,90 TWD
7. 8. 2025.20,00 TWD
6. 8. 2025.20,15 TWD
5. 8. 2025.20,05 TWD
4. 8. 2025.19,80 TWD
Access this data via the Eulerpool API

Applied BioCode prihod, EBIT, neto dohodak

  • 3 године

  • 5 година

  • 10 година

  • 25 godina

  • Максимално

Prihod
EBIT
Neto dohodak
Details
Date
Prihod
EBIT
Neto dohodak
1. јан 2019.
104,69 М TWD
-273,46 М TWD
-280,07 М TWD
1. јан 2020.
299,02 М TWD
-99,16 М TWD
-103,50 М TWD
1. јан 2021.
319,96 М TWD
-162,31 М TWD
-165,20 М TWD
1. јан 2022.
390,30 М TWD
-181,93 М TWD
-184,73 М TWD
1. јан 2023.
395,17 М TWD
-186,70 М TWD
-164,20 М TWD
1. јан 2024.
343,07 М TWD
-277,67 М TWD
-260,81 М TWD
1. јан 2025.
475,20 М TWD
-223,33 М TWD
-201,20 М TWD
1. јан 2026. (e)
0,00 TWD
0,00 TWD
0,00 TWD

Applied BioCode Izveštaj o dobitku, Bilans stanja, Izveštaj o toku gotovine

Zadnje ažurirano 3. авг 2026. 19:38
 
PRIHODМ TWD
RAST PRIHODA%
BRUTO MARŽA%
BRUTO DOHODAKМ TWD
EBITМ TWD
EBIT MARŽA%
NETO DOHODAKМ TWD
RAST NETO DOHOTKA%
AKCIJEМ
20132014201520162017201820192020202120222023202420252026e
26,0015,0023,0011,0026,0037,00104,00299,00319,00390,00395,00343,00475,00
-42,3153,33-52,17136,3642,31181,08187,506,6922,261,28-13,1638,48
7,6913,3326,0936,3630,7743,2450,0064,5559,2560,0067,8559,1854,74
2,002,006,004,008,0016,0052,00193,00189,00234,00268,00203,00260,00260,00
-83,00-162,00-221,00-194,00-263,00-267,00-273,00-99,00-162,00-181,00-186,00-277,00-223,00
-319,23-1.080,00-960,87-1.763,64-1.011,54-721,62-262,50-33,11-50,78-46,41-47,09-80,76-46,95
-208,00-71,00-21,00-135,00-263,00-268,00-280,00-103,00-165,00-184,00-164,00-260,00-201,00
-65,87-70,42542,8694,811,904,48-63,2160,1911,52-10,8758,54-22,69
102,65102,65102,6540,0546,6659,4271,1681,5981,7381,6981,77102,79102,65102,65
Detalji

Ključne figure izveštaja o dobitku

Prihod i rast prihoda

Prihod je početna tačka svakog izveštaja o dobitku — on meri ukupnu prodaju koju Applied BioCode generiše iz svoje osnovne delatnosti. Rast prihoda (izražen kao godišnja procentualna promena) je jedan od najvažnijih pokazatelja momentum-a poslovanja. Održavan rast iznad 10% godišnje se generalno smatra jakim, dok se opadajući prihod smatra ozbiljnim znakom upozorenja koji zahteva istraživanje.

Bruto marža

Bruto marža = (Prihod − Troškovi prodanih dobara) ÷ Prihod. Ona otkriva koliki procenat svakog dolara prihoda Applied BioCode zadržava nakon direktnih troškova proizvodnje. Visoke bruto marže (iznad 50%) su tipične za poslovanja sa malom imovinom poput softvera i brendova, dok kapitalno intenzivne industrije poput proizvodnje često prate ispod 30%. Uporedite bruto maržu Applied BioCode sa konkurentima iz industrije i pratite je tokom vremena da biste identifikovali poboljšanu ili pogoršanu moć određivanja cene.

EBIT i EBIT marža

EBIT meri operativni profit — ono što ostaje nakon oduzimanja svih operativnih rashoda (uključujući R&D, prodaju i administrativne troškove) od bruto profita. EBIT marža pokazuje ovo kao procenat od prihoda. Pošto isključuje kamate i poreze, EBIT omogućava fer poređenja između preduzeća sa različitim nivoima duga i poreskih jurisdikcija. Rastući EBIT marža ukazuje na poboljšanu operativnu efikasnost.

Neto dohodak i zarada po akciji (EPS)

Neto dohodak je finalni profit preduzeća nakon svih rashoda, kamata i poreza. Deljenje neto dohotka sa brojem izdatih akcija daje vam EPS — najuticajniju metriku u valuaciji akcija. Konzistentna EPS rast je primarni pokretač dugoročne apresijacije cene akcija. Uvek proverite da li EPS rast dolazi od genujnog poboljšanja profita ili od otkupa akcija koji smanjuju broj akcija.

Akcije u cirkulaciji

Ukupan broj akcija koje je Applied BioCode izdao. Opadajući broj akcija (kroz otkupe) povećava EPS i signalizira poverenje menadžmenta. Rastući broj akcija (kroz izdavanje akcija) razvodnjava postojeće akcionare. Uvek pratite ovaj broj zajedno sa EPS-om da biste dobili potpunu sliku kreiranja vrednosti po akciji.

Procene analitičara

Projicirane figure predstavljaju konsenzus procene stručnjaka iz oblasti analitike. Uporedite ove prognoze sa istorijskim stopama rasta Applied BioCode da biste procenili da li su očekivanja realna. Preduzeće koje konzistentno prekoračuje konsenzus prognoze ima tendenciju da vidi nagradu cene svojih akcija tokom vremena, dok ponovljene greške eroduju poverenje investitora.

Applied BioCode marže akcija

Analiza marži Applied BioCode prikazuje bruto marži, EBIT marži, kao i marži dobitka Applied BioCode. EBIT marža (EBIT/prodaja) pokazuje procenat prodaje koji ostaje kao operativni profit. Marža dobitka pokazuje procenat prodaje koji ostaje za Applied BioCode.
  • 3 године

  • 5 година

  • 10 година

  • 25 godina

  • Максимално

Bruto marža
EBIT marža
Marža dobitka
Details
Date
Bruto marža
EBIT marža
Marža dobitka
1. јан 2019.
50,59 %
-261,20 %
-267,52 %
1. јан 2020.
64,72 %
-33,16 %
-34,61 %
1. јан 2021.
59,18 %
-50,73 %
-51,63 %
1. јан 2022.
60,00 %
-46,61 %
-47,33 %
1. јан 2023.
68,01 %
-47,25 %
-41,55 %
1. јан 2024.
59,46 %
-80,94 %
-76,02 %
1. јан 2025.
54,90 %
-47,00 %
-42,34 %
1. јан 2026. (e)
54,90 %
0,00 %
0,00 %

Applied BioCode akcija prihod, EBIT, zarada po akciji

Applied BioCode zarada po akciji stoga pokazuje koliko prihoda je Applied BioCode ostvario po akciji u datom periodu. Zarada pre kamata i poreza po akciji pokazuje koliko operativnog profita odgovara svakoj akciji. Zarada po akciji pokazuje koliko profita pripada svakoj akciji.
  • 3 године

  • 5 година

  • 10 година

  • 25 godina

  • Максимално

Prihod po akciji
EBIT po akciji
Zarada po akciji
Details
Date
Prihod po akciji
EBIT po akciji
Zarada po akciji
1. јан 2019.
1,47 TWD
-3,84 TWD
-3,94 TWD
1. јан 2020.
3,66 TWD
-1,22 TWD
-1,27 TWD
1. јан 2021.
3,91 TWD
-1,99 TWD
-2,02 TWD
1. јан 2022.
4,78 TWD
-2,23 TWD
-2,26 TWD
1. јан 2023.
4,83 TWD
-2,28 TWD
-2,01 TWD
1. јан 2024.
3,34 TWD
-2,70 TWD
-2,54 TWD
1. јан 2025.
4,63 TWD
-2,18 TWD
-1,96 TWD
1. јан 2026. (e)
0,00 TWD
0,00 TWD
0,00 TWD

Applied BioCode poslovni model i analiza akcije

Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice.

Applied BioCode procene po Fair Value modelu

Detalji

Procena fer vrednosti

Šta je fer vrednost?

Fer vrednost je procena od čega je akcija zaista "vredna" zasnovana na njenim finansijskim fundamentalnim faktorima, nezavisno od trenutne tržišne cene. Ako je izračunata fer vrednost viša od trenutne cene akcije, akcija može biti potcenjena — i obrnuto. Ovaj grafikon prikazuje tri različita pristupa fer vrednosti kako biste mogli da ih međusobno proverite.

Fer vrednost zasnovana na zaradama

Izračunava se množenjem trenutne zarade po akciji (EPS) sa prosečnim istorijskim P/E odnosom tokom odabranog perioda od više godina. Glađenje tokom nekoliko godina filtrira privremene skokove ili padove. Ako ova fer vrednost premašuje tržišnu cenu, to sugeriše da je akcija jeftina u odnosu na svoju snagu zarade.

Primer: Fer vrednost (zarade) 2022 = EPS 2022 × Prosečan P/E 2019–2021

Fer vrednost zasnovana na prihodu

Izvedena množenjem prihoda po akciji sa prosečnim istorijskim price-to-sales odnosom. Ovaj metod je posebno koristan za kompanije sa volatilnom ili privremeno depresiranom zaradom, jer je prihod obično stabilniji od profita. Odgovara na pitanje: "Po kojoj ceni je tržište istorijski vrednilo svaki dolar prihoda ove kompanije?"

Primer: Fer vrednost (prihod) 2022 = Prihod po akciji 2022 × Prosečan P/S 2019–2021

Fer vrednost zasnovana na dividendi

Izračunava se deljenjem dividende po akciji sa prosečnim istorijskim prinosom od dividendi. Ovaj pristup je najozbiljniji za zrele, konzistentne kompanije koje plaćaju dividende. Ako je rezultirajuća fer vrednost viša od trenutne cene, to implicira da akcija nudi bolji prinos od njene istorijske srednje vrednosti.

Primer: Fer vrednost (dividenda) 2022 = Dividenda po akciji 2022 ÷ Prosečan prinos 2019–2021

Kako koristiti ovaj grafikon

Kada se sve tri linije fer vrednosti konverguju iznad trenutne cene, to pojačava slučaj da je akcija potcenjena. Kada se diverguju, istražite zašto — to može ukazati na strukturne promene u marginama, politici isplate ili stopi rasta. Buduće procene na desnoj strani proširuju analizu koristeći projektovane fundamentalne faktore, pomažući vam da procieniete da li trenutna cena već odražava očekivanja budućeg rasta.

Applied BioCode istorijski KGV, EBIT multiplikator i KUV

Applied BioCode godišnji prinosi

Detalji

Godišnji prinos

Šta ovaj grafikon prikazuje

Ovaj grafikon rastavi ukupan godišnji prinos u dve komponente: prinos od cene (dobici ili gubici od kretanja cene akcije) i prinos od dividendi (dohodak primljen od plaćanja dividendi). Zajedno, oni predstavljaju ukupan prinos koji bi investor zaradio u svakoj godini kalendara.

Prinos od cene

Prinos od cene meri procentualnu promenu cene akcije od 1. januara do 31. decembra svake godine. Pozitivne trake pokazuju da je akcija aprecirana; negativne trake pokazuju pad. Ovo je komponenta na koju se većina investitora fokusira, ali to samo deo priče govori — posebno za akcije koje plaćaju dividende.

Prinos od dividendi

Prinos od dividendi predstavlja dohodak generisan od dividendi plaćenih tokom godine, izražen kao procenat početne cene akcije. Iako može da izgleda mali u bilo kojoj godini (tipično 1–4% za uspostavljene kompanije), dividende se značajno složaju tokom decenija i istorijski su doprinele otprilike 40% ukupnih prinosa tržišta akcija.

Šta treba da tražite

Ispitajte koliko je godina pokazalo pozitivne nasuprot negativnih prinosa da biste procieniete konzistentnost. Akcija sa uglavnom pozitivnim godinama i manjim padovima sugeriše manji rizik. Takođe uporedite godišnje prinose sa benchmark indeksom — konzistentno nadmašivanje tržišta je karakteristika snažne investicije. Obratite pažnju na najgore godine: razumevanje rizika pada je jednako važno kao i lovljenje potencijala rasta.

Applied BioCode akcija u opticaju

Broj akcija kompanije Applied BioCode je bio 102,65 М u 2025. Ovo pokazuje na koliko akcija je Applied BioCode podeljena. Pošto su akcionari vlasnici kompanije, svaka akcija predstavlja mali dio vlasništva kompanije.
  • 3 године

  • 5 година

  • 10 година

  • 25 godina

  • Максимално

Broj akcija
Details
Date
Broj akcija
1. јан 2019.
71,16 М Akcije
1. јан 2020.
81,59 М Akcije
1. јан 2021.
81,73 М Akcije
1. јан 2022.
81,69 М Akcije
1. јан 2023.
81,77 М Akcije
1. јан 2024.
102,79 М Akcije
1. јан 2025.
102,65 М Akcije
1. јан 2026. (e)
102,65 М Akcije
Ciljne cene i prognoze za Applied BioCode nisu dostupne.

Struktura akcionara Applied BioCode

% Naziv
9,73018%
Hsu (Fu-Lung)
Hsu (Fu-Lung)
9,16736%
Maxwell Sensors Incorporation
Maxwell Sensors Incorporation
3,94085%
Eureka BioVenture Partners
Eureka BioVenture Partners
3,06682%
GVT Fund L.P.
GVT Fund L.P.
3,01164%
Celerus Diagnostics
Celerus Diagnostics
2,48303%
Cathay Venture Inc.
Cathay Venture Inc.

Applied BioCode Beneficial Ownership Filings (SEC 13D/G)

Free Float
69,4%
Float Shares
-
Shares Outstanding
-

Applied BioCode Извршни директори и управни одбор

14 members · 0 % women

Management

ZH

Mr. Zohn-Zen Ho

Founder, Chief Technology Officer, General Manager, Director · од 2008

LH

Mr. Liang-Kai Huang

Chief Financial Officer, Corporate Governance Officer

MA

Mr. Michael Aye

Vice President-Molecular Products

DW

Mr. Donald Wong

Vice President-Productions

YC

Mr. Youning Chen

Deputy General Manager-Taiwan Sub-Subsidiary

GK

Gerald Kowalski

Deputy General Manager-Operation

Board of Directors

JL

Mr. Jia-Long Lee

Chairman of the Board · од 2016

BJ

Mr. Benjamin Jen

Director

LL

Lizzie Lee

Director

WT

Mr. Wen-Jing Tsai

Independent Director

JT

James Tsu

Independent Director

JW

Jim Wu

Independent Director

Često postavljana pitanja o akciji Applied BioCode

The business model of Applied BioCode Corp is centered around providing innovative molecular diagnostics solutions. They specialize in the development, manufacture, and commercialization of barcode technology-based multiplex testing systems for diagnostics laboratories. With their proprietary BioCode-1000 system, they offer a cost-effective and scalable solution for high-throughput testing of various diseases such as cancer, infectious diseases, and genetic disorders. Applied BioCode Corp aims to improve patient outcomes by delivering accurate and timely diagnostic results to healthcare professionals. Their advanced technology, coupled with a commitment to continuous innovation, positions them as a leading player in the field of molecular diagnostics.

Applied BioCode Corp is primarily active in the biotechnology industry.

The main competitors of Applied BioCode Corp in the market include companies such as Illumina, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories, and QIAGEN.

Applied BioCode Corp is a leading biotechnology company specializing in developing and commercializing molecular diagnostic systems. Founded in [insert year], Applied BioCode Corp has a rich history in the field of biotech and has consistently delivered innovative solutions for healthcare professionals. The company is dedicated to improving patient care by revolutionizing diagnostic testing through its proprietary barcoded magnetic bead technology. With a team of highly skilled scientists and engineers, Applied BioCode Corp has gained recognition for its advanced diagnostic platforms that offer high throughput, multiplex capability, and cost-effectiveness. The company continues to expand its product portfolio and collaborate with industry partners to address the evolving needs of the healthcare industry.

Applied BioCode Corp has achieved several significant milestones in its journey. The company has made strides in the development and commercialization of its proprietary Barcoded Magnetic Bead (BMB) technology. This innovative technology offers multiplex testing capabilities, enabling simultaneous analysis of multiple targets, including genes, proteins, and pathogens. Applied BioCode Corp has successfully launched its FDA-cleared BioCode MDx 3000 system, which allows complex diagnostic testing with high precision and speed. Additionally, the company has secured strategic partnerships and collaborations with major healthcare institutions, facilitating the adoption of its BMB technology. Through these achievements, Applied BioCode Corp has established itself as a leader in the field of molecular diagnostics.

Applied BioCode Corp is primarily present in the United States, particularly in the state of California.

Applied BioCode Corp is a prominent biotechnology company that values innovation, integrity, and excellence. With a strong corporate philosophy, Applied BioCode Corp focuses on developing cutting-edge technologies and solutions to revolutionize diagnostics and improve patient care. By merging the fields of molecular diagnostics and multiplex biomarker detection, the company aims to address unmet clinical needs. Applied BioCode Corp is committed to providing accurate and efficient diagnostic products that empower healthcare professionals and ultimately enhance patient outcomes. With its forward-thinking approach and commitment to quality, Applied BioCode Corp strives to contribute to the advancement of healthcare and improve global health outcomes.

9 analysts currently rate the Applied BioCode stock: 0 recommend buying, 3 holding and 6 selling.

Converted at the current exchange rate, the Applied BioCode share trades at 0,81 EUR (30,20 TWD).

Applied BioCode Corp is a leading company in the field of molecular diagnostics and the development of digitally encoded barcode assays using multiple microbeads. The company utilizes its proprietary barcodes to enable complex biochemical analysis with high accuracy, reliability, and throughput capacity. The business model of Applied BioCode Corp is based on the development and commercialization of diagnostic systems and products for food and water analysis, clinical diagnostics, and research. The company offers innovative solutions to meet the needs of customers in various industries. Applied BioCode Corp's main division is the BioCode Gastrointestinal Pathogen Panel (GPP) diagnostic system, which allows for rapid and accurate diagnosis of gastrointestinal tract infections by simultaneously analyzing multiple samples for different bacteria, viruses, and parasites. Another product of the company is the BioCode Respiratory Pathogen Panel (RPP) system, which enables rapid and accurate diagnosis of respiratory infections by simultaneously analyzing multiple samples for different viruses and bacteria. The RPP provides an effective method for prevention, containment, and control of infectious diseases. Applied BioCode Corp also produces labeling products such as BioCode screening platforms to enable customers to accurately and timely identify pathogens. The company also offers a wide range of sampling methods and accessories to meet the requirements of diverse customers and applications. Applied BioCode Corp's products are distributed worldwide and are used in various industries, such as food and water analysis, clinical diagnostics, and research. The company focuses on offering innovative solutions to its customers to help meet their needs in terms of analysis, diagnosis, and results. Applied BioCode Corp also operates partnerships and collaborations with other companies to introduce and further develop its systems and products in new areas. The company is constantly striving to improve the quality and accuracy of its products while reducing costs to ensure high customer satisfaction. In conclusion, Applied BioCode Corp is a company that specializes in the development and commercialization of innovative diagnostic systems and products for food and water analysis, clinical diagnostics, and research. It offers its customers accurate and reliable solutions to meet their requirements and enhance their efficiency. With an advanced product portfolio, global trade partners, and a dedicated team of professionals, Applied BioCode Corp is undoubtedly one of the leading companies in the field of molecular diagnostics. Applied BioCode Corp is a leading company specializing in molecular diagnostics and the development of digitally encoded barcode assays using multiple microbeads. The company utilizes its proprietary barcodes to enable highly accurate, reliable, and high-throughput complex biochemical analyses. Their business model focuses on developing and marketing diagnostic systems and products for food and water analysis, clinical diagnostics, and research. They offer innovative solutions to meet the needs of customers in various industries. One of their main divisions is the BioCode Gastrointestinal Pathogen Panel (GPP) diagnostic system, which allows for rapid and accurate diagnosis of gastrointestinal infections by simultaneously analyzing multiple samples for various bacteria, viruses, and parasites. Another product is the BioCode Respiratory Pathogen Panel (RPP) system, providing fast and accurate diagnosis of respiratory infections by simultaneously analyzing multiple samples for different viruses and bacteria. The RPP offers an effective method for prevention, containment, and control of infectious diseases. Applied BioCode Corp also manufactures labeling products such as BioCode screening platforms, allowing for precise and timely identification of pathogens. They also offer a wide range of sampling methods and accessories to fulfill the requirements of different customers and applications. Their products are distributed worldwide and utilized in various industries including food and water analysis, clinical diagnostics, and research. The company focuses on providing customers with innovative solutions to fulfill their analytical, diagnostic, and result-related needs. They also engage in partnerships and collaborations with other companies to introduce and advance their systems and products in new areas. Applied BioCode Corp is committed to continuously improving the quality and accuracy of their products while reducing costs to ensure high customer satisfaction. In conclusion, Applied BioCode Corp is a specialized company that develops and markets innovative diagnostic systems and products for food and water analysis, clinical diagnostics, and research. Their accurate and reliable solutions help customers meet their requirements and increase efficiency. With their advanced product portfolio, global trade partnerships, and dedicated professional team, Applied BioCode Corp is a leading company in the field of molecular diagnostics.

Prihod se trenutno ne može izračunati za Applied BioCode.

Dobit se trenutno ne može izračunati za Applied BioCode.

KGV se trenutno ne može izračunati za Applied BioCode.

KUV se trenutno ne može izračunati za Applied BioCode.

Eulpool score kvaliteta za Applied BioCode je 4/10.

ISIN za Applied BioCode je KYG0488D1051. ISIN (International Securities Identification Number) je globalno jedinstveni identifikator za hartije od vrednosti.

Ticker za Applied BioCode je 6598.TW. Simbol tikera se koristi za trgovinu akcijama Applied BioCode na berzanskom tržištu.

Applied BioCode је исплаћивала дивиденде сваке године у протеклих 0 година.

Applied BioCode је додељена сектору 'Zdravstvo'.

Дивиденде компаније Applied BioCode се расподељују у TWD.